Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea published that Leqembi® (lecanemab) has been approved for treatment in patients with mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD (early AD).--- This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on May 24, 2024, at 12:55 p.m. CET.